Whalesbook
Glenmark Pharmaceuticals has launched the world's first nebulised, fixed-dose triple therapy for Chronic Obstructive Pulmonary Disease (COPD). The product, Nebzmart GFB Smartules and Airz FB Smartules, combines Glycopyrronium, Formoterol, and Budesonide to reduce airway obstruction and inflammation, improving lung function. This innovative treatment offers a simpler, more convenient option for patients, particularly those struggling with inhalers, marking a significant advancement in respiratory care and reinforcing Glenmark's leadership in the field. The company's shares saw a positive uptick following the announcement.